Natrecor, generic resiritide, is called a B-type natiruretic peptide, and is produced from the bacteria E coli using recumbent DNA technology. The FDA (Federal Drug Administration) approved this drug for in-hospital use for the intravenous treatment of decompensated congestive heart failure with a warning about possible kidney problems in 2001. The approval was given to Scios, which became a division of Johnson & Johnson in 2003.
Natrecor has not been shown to be more effective than other treatments for the approved use, but it costs up to $700 a session, about 50 times more than standard treatment options. Natrecor sales reached almost $700 million in 2005. Johnson & Johnson is being investigated for marketing Natrecor for unapproved uses. See Natrecor Lawsuits, Litigation, and Lawyers for more information. Johnson & Johnson is suspected of making direct or indirect Natrecor claims that the drug can be used for purposes other than FDA-approved.
Check out the following articles for more information about Natrecor, filing an Natrecor lawsuit and finding an Natrecor attorney: